e Granulocyte Colony Stimulating Factor (G-CSF) medicines that stimulate the production of white blood cells and are primarily used to reduce the risk of infections in oncology patients receiving chemotherapy. Granix (short-acting G-CSF) is approved in the United States and is approved via a Biologics License Application by the FDA in 2012 and launched in 2013. The product is also approved and available in Japan and certain other Rest of the World (ROW) markets. In December 2014, the FDA also approved Granix injection for self-administration by patients and caregivers. Lonquex (long-acting G-CSF) is a G-CSF with the active ingredient lipegfilgrastim, a novel glycoPEGylated (PEG; polyethylene glycol) filgrastim molecule. Women’s Health The company’s women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel), and Zoely along with other local products that are marketed in the United States, Europe and ROW. Plan B One-Step OTC/Rx (levonorgestrel) is an emergency oral contraceptive which consists of a single tablet dose of levonorgestrel for emergency contraception. ParaGard T380 A (intrauterine copper contraceptive) is a non-hormonal intrauterine contraceptive marketed in the United States. Other Activities The company’s other activities comprise its OTC business. Consumer Healthcare Joint Venture PGT Healthcare (PGT) is its consumer healthcare joint venture with The Procter & Gamble Company. The joint venture includes its OTC medicines and vitamins, minerals and food supplements (VMS). PGT manufactures and markets approximately 200 consumer healthcare brands in 70 countries worldwide. Its portfolio includes cough and cold brand Vicks, Germany’s OTC brand ratiopharm, and other brands. Strategy The company seeks to capitalize on its advantages, including the largest generic medicines business in the world, a focused specialty business, a unique OTC business and its integrated R&D and API capabilities to provide patients with integrated, outcome-focused solutions. The key elements of its strategy consist of the following: solidifying its foundation and driving organic growth; focusing on key growth markets; maintaining Copaxone and other key specialty products; solidifying leadership positions in core therapeutic areas; pursuing strategic business development initiatives; and executing on cost reduction program. Significant Events In April 2015, OncoGenex Pharmaceuticals, Inc. announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex would regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. History Teva Pharmaceutical Industries Limited was founded in 1901.
teva pharmaceutical-sp adr
(TEVA:New York Consolidated)
5 Basel Street
P.O. Box 3190
Petach Tikva, 49131
Phone: 972 3 926 7267
Fax: 972 3 923 4050www.tevapharm.com
|Abbott Laboratories||$50.50 USD||-0.19|
|AbbVie Inc||$69.73 USD||-0.28|
|AstraZeneca PLC||4,342 GBp||+22.00|
|Eli Lilly & Co||$84.14 USD||-0.37|
|Medtronic PLC||$78.00 USD||-0.39|
|View Industry Companies|
Sponsored Financial Commentaries
To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.